Hydrocortisone Panpharma

Hydrocortisone Panpharma is a prescription‑only corticosteroid medication that contains the active ingredient hydrocortisone. It is supplied for intramuscular or intravenous administration and is marketed in the European Union. As a glucocorticoid, it mimics the action of endogenous cortisol and is used under medical supervision for conditions requiring rapid anti‑inflammatory or adrenal hormone replacement. The formulation is intended for management of adrenal insufficiency, severe allergic reactions, and should be administered by professionals.

Hydrocortisone Panpharma is prescribed for conditions that require rapid glucocorticoid replacement or potent anti‑inflammatory action.

- Adrenal insufficiency (primary or secondary) requiring hormone replacement. - Acute adrenal crisis presenting with hypotension and shock. - Severe allergic or anaphylactic reactions where immediate anti‑inflammatory effect is needed. - Acute inflammatory disorders such as severe asthma exacerbations or systemic vasculitis. - Pre‑operative management of patients at risk of adrenal suppression. - Treatment of severe skin inflammation (e.g., extensive eczema or dermatitis) when systemic therapy is indicated. - Management of septic shock where cortisol deficiency is suspected.

Hydrocortisone Panpharma may cause a range of adverse reactions, varying from mild and transient to potentially serious.

Common: - Injection site pain or erythema. - Fluid retention leading to mild edema. - Elevated blood glucose, especially in diabetic patients. - Mood changes such as anxiety or insomnia. - Gastrointestinal discomfort, nausea or dyspepsia. - Headache or dizziness. - Increased appetite and weight gain. - Skin thinning or bruising.

Serious: - Severe hypersensitivity reactions including anaphylaxis. - Acute adrenal suppression after abrupt discontinuation. - Significant hypertension or cardiovascular events. - Opportunistic infections due to immunosuppression. - Osteonecrosis or severe bone loss with prolonged use. - Hyperglycemia leading to diabetic ketoacidosis. - Peptic ulcer bleeding. - Psychiatric disturbances such as psychosis.

When prescribing Hydrocortisone Panpharma, clinicians should evaluate patient‑specific factors and monitor for potential complications.

- Assess adrenal function before initiating therapy and consider stress‑dose adjustments. - Use the lowest effective dose for the shortest duration required. - Monitor blood pressure, glucose, and electrolytes during treatment. - Caution in patients with uncontrolled diabetes, hypertension, or active infections. - Avoid abrupt discontinuation to prevent adrenal insufficiency; taper gradually when long‑term therapy is stopped. - Evaluate for psychiatric symptoms, especially in high‑dose regimens. - Consider bone health monitoring (e.g., DEXA scan) in patients receiving prolonged therapy.

Hydrocortisone Panpharma can alter the pharmacokinetics or pharmacodynamics of several concomitant medicines; awareness of key interactions helps prevent adverse outcomes.

Avoid: - Concurrent use of potent CYP3A4 inducers (e.g., rifampin, phenytoin) that may reduce hydrocortisone exposure. - Co‑administration with systemic anticoagulants may increase bleeding risk due to glucocorticoid‑induced platelet changes.

Use with caution: - Non‑steroidal anti‑inflammatory drugs (NSAIDs) may increase risk of gastrointestinal ulceration. - Antidiabetic agents may require dose adjustment because hydrocortisone raises blood glucose. - Vaccines, especially live attenuated, may have reduced efficacy or increased infection risk. - Loop diuretics can exacerbate electrolyte disturbances when combined with glucocorticoids.